FibroGen Revenue and Competitors
Estimated Revenue & Valuation
- FibroGen's estimated annual revenue is currently $283.8M per year.
- FibroGen's estimated revenue per employee is $441,306
- FibroGen's total funding is $188M.
- FibroGen's current valuation is $1.3B. (January 2022)
Employee Data
- FibroGen has 643 Employees.
- FibroGen grew their employee count by -15% last year.
FibroGen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | Chief Technical Officer | Reveal Email/Phone |
4 | SVP, China Operations | Reveal Email/Phone |
5 | VP, Manufacturing and Supply Operations | Reveal Email/Phone |
6 | VP Technical Development | Reveal Email/Phone |
7 | VP, Intellectual Property | Reveal Email/Phone |
8 | SVP, Regulatory Affairs and Drug Safety | Reveal Email/Phone |
9 | Head Talent Acquisition | Reveal Email/Phone |
10 | VP - Corporate Strategy / Investor Relations | Reveal Email/Phone |
FibroGen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is FibroGen?
FibroGen has developed the only commercially viable method known to produce human collagen and human gelatin in recombinant systems. FibroGen will exploit this technology by becoming both a bulk product supplier for the pharmaceutical and medical device industries as well as a developer and commercializer of injectable products, wound management products, and gelatin stabilizers. FibroGen's corporate collaborations include a partnership with Taisho Pharmaceutical Company of Japan to discover and develop human monoclonal antibody therapeutics for renal fibrosis and chronic transplant rejection.
keywords:Biotechnology
$188M
Total Funding
643
Number of Employees
$283.8M
Revenue (est)
-15%
Employee Growth %
$1.3B
Valuation
N/A
Accelerator
FibroGen News
A FibroGen Inc. investor filed suit in Delaware against current and former members of its board and management, claiming two of them sold...
356 IPF Patients Enrolled -. - Topline Data Anticipated Mid-2023 -. SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen,...
The securities action is In re FibroGen Inc. Securities Litigation, case number 3:21-cv-02623, in the U.S. District Court for the Northern...
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadus ...
Other Companies in San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $114.7M | 645 | 20% | $7.1M |
#2 | $7.5M | 645 | 123% | N/A |
#3 | $114.9M | 646 | -1% | $330M |
#4 | $201.9M | 646 | 21% | N/A |
#5 | $115M | 647 | 14% | $332M |